ArticleJournal of the American Heart Association2026
Persistent Cardiovascular Burden and Independent Association Among Cancer Survivors in the United States, 2016 to 2024.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiovascular disease (CVD) is a leading cause of morbidity among cancer survivors. However, contemporary trends and independent association between cancer survivorship and prevalent CVD remain incompletely characterized.
methodsUsing 2016 to 2024 Behavioral Risk Factor Surveillance System data, we analyzed 2 nationally representative cohorts of US adults. A trend cohort (n=3 642 415) assessed age-standardized CVD prevalence via Joinpoint regression. An association cohort (n=829 958) isolated the association between cancer survivorship and CVD using inverse probability of treatment weighting.
resultsFrom 2016 to 2024, age-standardized CVD prevalence among cancer survivors was persistently double that of the general population (12.9%-15.0% versus 6.8%), with no significant temporal decline. In unadjusted analysis to determine the absolute burden, survivors had 11.7% higher CVD prevalence than controls. After inverse probability of treatment weighting adjustment, a significant absolute prevalence difference of 3.0% persisted. Consequently, cancer survivorship was independently associated with prevalent CVD (odds ratio [OR], 1.22 [95% CI, 1.18-1.27=;
conclusionsThe CVD burden among US cancer survivors remains persistently high. Independent of traditional factors, cancer survivorship is associated with a distinct cardiovascular burden, particularly among younger individuals and those with a low-risk metabolic profile. These findings support extending cardiovascular surveillance to conventionally low-risk subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.